NOW AVAILABLE: NGS Myeloid Panel! MLabs is excited to announce the addition of our new NGS Myeloid
Panel: For any myeloid or suspected myeloid neoplasm.
Michigan Medicine has earned the No. 15 spot in Newsweek’s 2020 World’s Best Hospitals list.
The institution also came in fifth in the United States and was named top hospital in Michigan.
Serology testing for SARS-CoV-2 is now available for ordering. A separate process for testing and screening of health care workers and Michigan Medicine affiliates will be communicated in the coming weeks.
USCAP has its eyes on you as you navigate the exhibit hall, posters, platform sessions special courses, Long Course on Major Advances in the Diagnosis and Management of Breast Diseases, short courses, interactive microscopy courses...
Once again, MLabs will be exhibiting at The FSP’s 46th Annual Pathology Conference: Updates and Practical Approaches in Pathology is designed to provide pathologists with education surrounding...
The ASHG 2019 Annual Meeting provides a forum for the presentation and discussion of cutting-edge science in all areas of human genetics. It will be held in...
Reference laboratory services available through Michigan Medicine now have a new name: Michigan Medicine Laboratories.
Many patients living with metastatic breast cancer (mBS) now have a new treatment option.
In May 2019, the FDA approved a new targeted therapy, alpelisib (Piqray®). An oral medication intended to be used in combination with fulvestrant (Faslodex®), Piqray® is...
MLabs, and the Department of Pathology laboratories at Michigan Medicine, recognized leaders for advanced diagnostic testing, are now participating in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial.
MLabs next-generation sequencing (NGS) offerings include Solid Tumor, Lung Cancer, Colorectal Cancer, and Melanoma NGS Panels. These NGS tests target 50 genes to detect substitution and insertion/deletion mutations (35 genes), gene amplifications (19 genes), and gene fusions (21 genes) including NTRK gene fusions...